Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038278 | 1.00 | LCK (0.65) | LCKSRC | |
| SCHEMBL4037424 | 0.94 | LCK (0.75) | LCKSRC | |
| SCHEMBL4039733 | 0.94 | LCK (0.75) | LCKSRC | |
| SCHEMBL4039926 | 0.89 | LCK (0.73) | LCKSRC | |
| SCHEMBL4040687 | 0.89 | LCK (0.64) | LCKSRC | |
| SCHEMBL4036163 | 0.89 | LCK (0.64) | LCKSRC | |
| SCHEMBL4045378 | 0.88 | LCK (0.72) | LCKSRC | |
| SCHEMBL4038587 | 0.84 | LCK (0.89) | LCKSRC | |
| SCHEMBL4036702 | 0.84 | LCK (0.89) | LCKSRC | |
| SCHEMBL4042825 | 0.84 | LCK (0.63) | LCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | claimed |
| EP-1601354-A4 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2009-08-12 | — | — | EP | claimed |
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1601354-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2005017126-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| EP-1066286-A4 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-02-11 | — | — | EP | claimed |
| EP-1066286-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999045009-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-10 | — | — | WO | claimed |
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | disclosed |
| US-5990109-A | NOVEL COMPOUNDS, METHODS OF THEIR SYNTHESIS, AND THEIR USE IN TREATING VARIOUS TYROSINE KINASE-ASSOCIATED IMMUNOLOGICAL DISORDERS, SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GRAFT VS. HOST DISEASE, LUPUS, PSORIASIS AND ASTHMA | BRISTOL-MYERS SQUIBB CO. (US) | 1999-11-23 | — | — | US | disclosed |